About this trial
Scabies is highly contagious,pruritic infestation of skin.Various treatment modalities have been used but search for ideal scabicide is ongoing.we wnt to coduct this study to compare the outcome of permethrin verses ivermectin in children for treatment of scabies .This randomized clinical trial will be done in children hospital lahore for 12 months.Sample size of 90 cases;30 in each group will be included through non probability consecutive sampling.Then patient will be randomly divided into 3 groups.In group A patient will be given 5% permethrin topical application to whole body single application. In Group B ,patients will be given topical permethrin for twice application 24 hrs appart ,In group C patients will be given Tablet Ivermectin single dose 200microgram/kg.Then patients will be examined after 2 weeks and 4 weeks for no of lesions and pruritis and cure will be labeled.All this information will be recorded on performa .Data will be entered and analysed by using SPSS version 26.Three groups will be compared for cure by using chi-square test.P value less than and equal to 0.05 will be considered as significant.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 6-15
Both genders
Diagnosed with scabies (as per operational definition)
Disqualifiers
Children with recurrent scabies on medical record
Known allergy to ivermectin or permethrin.
Widespread eczema or impetigo.
Liver dysfunction or renal failure
Trial design
Parallel
Treatments tested in this trial
Permethrin Cream, 5%
DrugPermethrin 5% cream will be given as a single application
Permethrin Cream, 5%
DrugPermethrin Cream will be given as twice application
Ivermectin 200 µg/kg
DrugGroup C will be given Tab Ivermectin
Treatment groups
Trial outcomes
Primary outcomes
Cure of scabies.
Cure will be labeled if greater han 50% reduction in no of lesions and pruritis observed after 4 weeks of treatment.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: